PharmaCyte Biotech Cash Flow Statement

Financials in millions USD. Fiscal year is May - April.

Millions USD. Fiscal year is May - Apr.

Year	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013 - 2008
Net Income	-4.32	-4.24	-3.55	-3.83	-4.07	-6.83	-4.44	-6.06	-9.93	-27.25	Upgrade
Share-Based Compensation	0.65	0.11	0.44	1.22	1.02	1.84	1.13	2.59	7.04	17.93	Upgrade
Other Operating Activities	-0.13	0.01	-0.22	0.27	0.17	-0.09	-0.02	-0.87	-1.67	7.77	Upgrade
Operating Cash Flow	-3.79	-4.12	-3.33	-2.34	-2.88	-5.08	-3.34	-4.35	-4.56	-1.55	Upgrade
Acquisitions	0	0	0	0	0	0	0	0	0	-0.05	Upgrade
Other Investing Activities	-	-	-	-	-	-	-	-	-	-3.51	Upgrade
Investing Cash Flow	0	0	0	0	0	0	0	0	0	-3.56	Upgrade
Share Issuance / Repurchase	-13.56	87.36	4.7	2.66	2.34	2.68	4.88	3.57	3.79	8.51	Upgrade
Debt Issued / Paid	0	-0.05	-0.06	0.06	0	0	0	0	-0.14	0.02	Upgrade
Financing Cash Flow	-13.56	87.31	4.64	2.73	2.34	2.68	4.88	3.57	3.64	8.53	Upgrade
Exchange Rate Effect	-0.01	0	0	-0.01	-0.01	-0.01	0	-0	0	0	Upgrade
Net Cash Flow	-17.36	83.2	1.31	0.38	-0.54	-2.4	1.54	-0.78	-0.92	3.42	Upgrade
Free Cash Flow	-3.79	-4.12	-3.33	-2.34	-2.88	-5.08	-3.34	-4.35	-4.56	-1.55	Upgrade
Free Cash Flow Per Share	-0.20	-0.27	-2.30	-2.59	-3.92	-7.87	-5.93	-8.66	-9.71	-4.00	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).